{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:46:20Z","timestamp":1782470780725,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.eprac.2026.03.002","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:15:42Z","timestamp":1773159342000},"page":"1108-1114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low Serum Insulin-Like Growth Factor-1 as a Predictor of Fibrosis Burden in Metabolic-Associated Fatty Liver Disease"],"prefix":"10.1016","volume":"32","author":[{"given":"Wenzhen","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangfeng","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2540-8590","authenticated-orcid":false,"given":"Xueyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.eprac.2026.03.002_bib1","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2026.03.002_bib2","first-page":"283","article-title":"Incidence of hepatocellular carcinoma in Metabolic dysfunction-associated steatotic liver disease: a reconstructed individual patient data meta-analysis","volume":"20","author":"Lim","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.002_bib3","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the Most rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.002_bib4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.eprac.2026.03.002_bib5","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/liv.13397","article-title":"Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: an age-dependent risk profiling study","volume":"37","author":"Petta","year":"2017","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.eprac.2026.03.002_bib6","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1210\/en.2013-2086","article-title":"Liver-specific GH receptor gene-disrupted (LiGHRKO) mice have decreased endocrine IGF-I, increased local IGF-I, and altered body size, body composition, and adipokine profiles","volume":"155","author":"List","year":"2014","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.002_bib7","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1530\/EJE-22-0034","article-title":"Low IGF1 and high IGFBP1 predict diabetes onset in prediabetic patients","volume":"187","author":"Meyer","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.002_bib8","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1210\/endrev\/bnaf022","article-title":"Opposing metabolic effects of growth hormone and IGF-I: review and clinical implications","volume":"46","author":"Laron","year":"2025","journal-title":"Endocr Rev"},{"issue":"7","key":"10.1016\/j.eprac.2026.03.002_bib9","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/s41366-025-01773-x","article-title":"IGFBP-1 and IGF-I in relation to adiposity and mortality from midlife to old age in the Swedish Adoption\/Twin Study of Aging","volume":"49","author":"Lewitt","year":"2025","journal-title":"Int J Obes (Lond)"},{"issue":"7","key":"10.1016\/j.eprac.2026.03.002_bib10","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/hepr.12408","article-title":"Lower levels of insulin-like growth factor-1 standard deviation score are associated with histological severity of non-alcoholic fatty liver disease","volume":"45","author":"Sumida","year":"2015","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.002_bib11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1478-3231.2008.01770.x","article-title":"Enhanced actions of insulin-like growth factor-I and interferon-alpha co-administration in experimental cirrhosis","volume":"29","author":"Tutau","year":"2009","journal-title":"Liver Int"},{"issue":"10","key":"10.1016\/j.eprac.2026.03.002_bib12","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/oby.70005","article-title":"Screening for MASLD and advanced fibrosis among patients with obesity: a cost-effectiveness analysis","volume":"33","author":"Mohanty","year":"2025","journal-title":"Obesity (Silver Spring)"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.002_bib13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3892\/mco.2023.2676","article-title":"FIB-4 index and NAFLD fibrosis score are useful indicators for screening high-risk groups of non-viral hepatocellular carcinoma","volume":"19","author":"Imai","year":"2023","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.eprac.2026.03.002_bib14","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cgh.2025.07.011","article-title":"Longitudinal changes in fibrosis markers: monitoring Stiffness\/Fibrosis progression and prognostic outcomes in MASLD","volume":"24","author":"Zhou","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"13","key":"10.1016\/j.eprac.2026.03.002_bib15","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1016\/j.cgh.2025.02.030","article-title":"Insulin-like growth Factor-1 reflects liver disease stage and improves prediction of liver-related mortality","volume":"23","author":"Schneider","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.002_bib16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12986-025-00942-z","article-title":"Association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): data from the NHANES III (1988-1994)","volume":"22","author":"Zhang","year":"2025","journal-title":"Nutr Metabolism"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.002_bib17","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41419-019-1670-6","article-title":"Insulin-like growth factor-1 attenuates oxidative stress-induced hepatocyte premature senescence in liver fibrogenesis via regulating nuclear p53-progerin interaction","volume":"10","author":"Luo","year":"2019","journal-title":"Cell Death Dis"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.002_bib18","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1128\/MCB.17.3.1595","article-title":"Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt","volume":"17","author":"Kulik","year":"1997","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.eprac.2026.03.002_bib19","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3389\/fnagi.2017.00365","article-title":"Insulin-Like growth Factor-1 and neuroinflammation","volume":"9","author":"Labandeira-Garcia","year":"2017","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.002_bib20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/apt.18289","article-title":"Insulin-like growth factor-1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver-related mortality","volume":"61","author":"Hartl","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.002_bib21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41574-024-01037-0","article-title":"Liver-specific actions of GH and IGF1 that protect against MASLD","volume":"21","author":"Kineman","year":"2025","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.002_bib22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.14740\/jocmr2761w","article-title":"Insulin-Like growth Factor-1 deficiency and cirrhosis establishment","volume":"9","author":"de la Garza","year":"2017","journal-title":"J Clin Med Res"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.002_bib23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12967-017-1198-4","article-title":"Experimental approach to IGF-1 therapy in CCl(4)-induced acute liver damage in healthy controls and mice with partial IGF-1 deficiency","volume":"15","author":"Morales-Garza","year":"2017","journal-title":"J Transl Med"},{"key":"10.1016\/j.eprac.2026.03.002_bib24","article-title":"Insulin-like growth factor 1 predicts decompensation and long-term prognosis in patients with compensated cirrhosis","volume":"10","author":"Saeki","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.eprac.2026.03.002_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/srep34605","article-title":"IGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner","volume":"6","author":"Nishizawa","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.eprac.2026.03.002_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2021.100560","article-title":"IGF-1 alleviates CCL4-induced hepatic cirrhosis and dysfunction of intestinal barrier through inhibition TLR4\/NF-kappaB signaling mediated by down-regulation HMGB1","volume":"26","author":"Zhao","year":"2021","journal-title":"Ann Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.002_bib27","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3390\/cells12040517","article-title":"The role of growth hormone and insulin growth factor 1 in the development of non-alcoholic Steato-Hepatitis: a systematic review","volume":"12","author":"Cristin","year":"2023","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.eprac.2026.03.002_bib28","doi-asserted-by":"crossref","first-page":"e3624","DOI":"10.1210\/clinem\/dgac405","article-title":"The GH\/IGF-1 axis is associated with intrahepatic lipid content and hepatocellular damage in Overweight\/Obesity","volume":"107","author":"Dichtel","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.002_bib29","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jhep.2005.03.025","article-title":"Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial","volume":"43","author":"Conchillo","year":"2005","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2026.03.002_bib30","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1053\/gast.1997.v113.pm9352873","article-title":"Hepatoprotective effects of insulin-like growth factor I in rats with carbon tetrachloride-induced cirrhosis","volume":"113","author":"Castilla-Cortazar","year":"1997","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.002_bib31","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/hep.23412","article-title":"Insulin-like growth factor I gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats","volume":"51","author":"Sobrevals","year":"2010","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.eprac.2026.03.002_bib32","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1161\/ATVBAHA.107.156257","article-title":"IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice","volume":"27","author":"Sukhanov","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"10.1016\/j.eprac.2026.03.002_bib33","first-page":"3077","article-title":"Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance","volume":"85","author":"Cusi","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.eprac.2026.03.002_bib34","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2337\/db05-1646","article-title":"Effects of recombinant human IGF-I\/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes","volume":"55","author":"Saukkonen","year":"2006","journal-title":"Diabetes"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26008086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26008086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:49:33Z","timestamp":1782467373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26008086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1530891X26008086"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.03.002","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low Serum Insulin-Like Growth Factor-1 as a Predictor of Fibrosis Burden in Metabolic-Associated Fatty Liver Disease","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the AACE.","name":"copyright","label":"Copyright"}]}}